ArticleNeuroradiology2025
Prognostic significance of frailty in chronic subdural hematoma: implications for treatment selection in the era of middle meningeal artery embolization.
Article in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Temporal Muscle Thickness Is a Prognostic Factor for Neurological Recovery After Surgery for Chronic Subdural Hematoma.Diagnostics (Basel, Switzerland) · 2026Article
- Frailty-driven anesthesia decisions in recurrent chronic subdural hematoma: Is it time to embrace embolization under local anesthesia?Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMiddle meningeal artery embolization (MMAE) as a standalone or adjunctive therapy has emerged as an efficacious and safe treatment for chronic/subacute subdural hematoma (csaSDH). The objective of this study is to compare the prognostic significance of frailty in csaSDH patients treated with MMAE alone or with craniotomy/burr hole (CBH).
methodsHospitalization records were identified in the National Inpatient Sample (2016-2020) and the cohort was stratified by increasing frailty thresholds, quantified by the Risk Analysis Index (RAI). Effect sizes of frailty tiers for poor outcome (defined as non-routine discharge disposition) produced from multivariable logistic regression models and discrimination (c-statistic) were evaluated separately in the MMAE only and CBH sub-cohorts.
resultsThis analysis identified 13,390 csaSDH hospitalizations, of which 595 (5%) documented treatment with MMAE only. Although all frailty tiers of the categorical RAI were significantly associated with poor outcome in the CBH cohort, lower effect sizes were observed in the MMAE cohort. Discrimination of RAI for poor outcome was significantly greater in the CBH cohort compared to the MMAE only cohort.
conclusionIn comparison to surgical evacuation, frailty demonstrated lower effect sizes and worse discrimination for poor outcomes in patients treated with MMAE, suggesting that frail patients may be more likely to achieve better outcomes following this less invasive therapy. MMAE may be considered as a first-line or standalone treatment in certain patients.
Indexed as
Identifiers
40116945What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.